Biology of Blood and Marrow Transplantation

ELSEVIER

ASBMT™
American Society for Blood and Marrow Transplantation

Alternative Donors

Reduction in Mortality after Umbilical Cord Blood Transplantation in Children Over a 20-Year Period (1995-2014)

Check for updates

Lisa P. Spees[1], Paul L. Martin[2], Joanne Kurtzberg[2], Andre Stokhuyzen[2], Lauren McGill[2], Vinod K. Prasad[2], Timothy A. Driscoll[2], Suhag H. Parikh[2], Kristin M. Page[2], Richard Vinesett[2], Christopher Severyn[3], Anthony D. Sung[4], Alan D. Proia[5], Kirsten Jenkins[6], Mehreen Arshad[6], William J. Steinbach[6], Patrick C. Seed[7], Matthew S. Kelly[6],*

[1] The Cecil G. Sheps Center for Health Services Research, University of North Carolina at Chapel Hill Gillings School of Global Public Health, Chapel Hill, North Carolina
[2] Division of Pediatric Blood and Marrow Transplant, Duke University Medical Center, Durham, North Carolina
[3] Division of Pediatric Hematology-Oncology, Lucille Packard Children's Hospital, Stanford University, Palo Alto, California
[4] Division of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute, Duke University, Durham, North Carolina
[5] Department of Pathology, Duke University Medical Center, Durham, North Carolina
[6] Division of Pediatric Infectious Diseases, Duke University Medical Center, Durham, North Carolina
[7] Division of Pediatric Infectious Diseases, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

A B S T R A C T

Infections and graft-versus-host disease (GVHD) have historically resulted in high mortality among children undergoing umbilical cord blood transplantation (UCBT). However, recent advances in clinical practice have likely improved outcomes of these patients. We conducted a retrospective cohort study of children (<18 years of age) undergoing UCBT at Duke University between January 1, 1995 and December 31, 2014. We compared 2-year all-cause and cause-specific mortality during 3 time periods based on year of transplantation (1995 to 2001, 2002 to 2007, and 2008 to 2014). We used multivariable Cox regression to identify demographic and UCBT characteristics that were associated with all-cause mortality, transplantation-related mortality, and death from invasive aspergillosis after adjustment for time period. During the 20-year study period 824 children underwent UCBT. Two-year all-cause mortality declined from 48% in 1995 to 2001 to 30% in 2008 to 2014 (P = .0002). White race and nonmalignant UCBT indications were associated with lower mortality. Black children tended to have a higher risk of death for which GVHD (18% versus 11%; P = .06) or graft failure (9% versus 3%; P = .01) were contributory than white children. Comparing 2008 to 2014 with 1995 to 2001, more than half (59%) of the reduced mortality was attributable to a reduction in infectious mortality, with 45% specifically related to reduced mortality from invasive aspergillosis. Antifungal prophylaxis with voriconazole was associated with lower mortality from invasive aspergillosis than low-dose amphotericin B lipid complex (hazard ratio, .09; 95% confidence interval, .01 to .76). With the decline in mortality from invasive aspergillosis, adenovirus and cytomegalovirus have become the most frequent infectious causes of death in children after UCBT. Advances in clinical practice over the past 20 years improved survival of children after UCBT. Reduced mortality from infections, particularly invasive aspergillosis, accounted for the largest improvement in survival and was associated with use of voriconazole for antifungal prophylaxis.

© 2018 American Society for Blood and Marrow Transplantation.

Allogeneic hematopoietic stem cell transplantation (HSCT) is used to treat a growing number of malignant and nonmalignant conditions in children. When available, bone marrow from an HLA-matched sibling is the preferred donor source for allogeneic stem cell transplantation. However, less than 40% of children requiring a stem cell transplant have a matched sibling donor [1]. Banked unrelated donor umbilical cord blood (UCB) has been used for the past 25 years as an alternative donor for patients lacking a matched sibling or matched unrelated adult donor [2]. Historically, infections, graft-versus-host disease (GVHD), graft failure or delayed engraftment, and regimen-related toxicity resulted in high mortality after unrelated donor UCB transplantation (UCBT) [3−5]. However, advances in donor selection and clinical care over the past several decades have likely improved outcomes of UCBT [6,7]. Other advances include the introduction of several new antifungal medications, use of steroid-sparing GVHD prophylaxis, and

access to defibrotide for the treatment of severe veno-occlusive disease (VOD) [8].

In this study we examined mortality over time in the largest single-center cohort of pediatric UCBT recipients reported to date. As secondary objectives we evaluated for temporal changes in cause-specific mortality and sought to identify changes in clinical practice that influenced survival of children after UCBT.

METHODS
Study Population

We performed a retrospective cohort study of children younger than 18 years of age undergoing their first UCBT through the Duke University Pediatric Blood and Marrow Transplant program between January 1, 1995 and December 31, 2014. The study protocol was approved by the Duke University Institutional Review Board.

Transplantation Practices

Throughout the study period patients were cared for on a dedicated unit containing positive-pressure, high-efficiency particulate air−filtered rooms. Cyclosporine in combination with corticosteroids was the most frequent GVHD prophylaxis regimen before 2006, whereas during more recent years most children received cyclosporine plus mycophenolate mofetil. Low-dose heparin (100 units/kg/day administered as a continuous i.v. infusion) was used for VOD prophylaxis until 2013, after which prophylaxis with ursodiol became standard practice. Defibrotide was available for the treatment of severe VOD either through a clinical trial or a compassionate use program beginning in 1998. Throughout the study period low-dose acyclovir (250 mg/m^2 per dose given i.v. every 12 hours) was administered to UCBT recipients with serologic evidence of prior infection with herpes simplex viruses. For *Pneumocystis jirovecii* prophylaxis, children received trimethoprim-sulfamethoxazole starting at the time of hospital admission and continuing until 2 days before UCBT, followed by inhaled or i.v. pentamidine starting 30 days after transplantation. Before September 2003 antifungal prophylaxis was most frequently provided with low-dose amphotericin B lipid complex (.2 mg/kg i.v. once daily). In September 2003 prophylaxis with voriconazole (4 mg/kg i.v. or p.o. twice daily) was implemented for most UBCT recipients; no loading dose was provided, and plasma trough voriconazole levels were not routinely monitored. Antifungal prophylaxis was started on the day after the transplantation date and continued for 100 days after UCBT or while the patient remained on immunosuppressive prophylaxis or therapy for GVHD. Throughout the study period routine antibacterial prophylaxis was not used.

Data Sources and Measures

Patient demographic data and transplant characteristics were obtained from the Duke Enterprise Data Unified Content Explorer research portal and a secure database maintained by the Duke University Pediatric Blood and Marrow Transplant program [9]. Causes of death were identified through review of the Pediatric Blood and Marrow Transplant database and the electronic medical record, including autopsy reports (when available), provider notes, and the results of microbiologic testing. We considered transplant-related mortality to be death from any cause other than progressive or recurrent malignancy (primary disease). To accurately determine the contribution of infections to the mortality of children after UCBT, we chose to classify fatal infections and GVHD as the cause of death when patients were receiving corticosteroids or other treatment for GVHD in the 1 month preceding death from an infection. Invasive fungal diseases were classified as possible, probable, or proven according to definitions developed by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group Consensus Group [10]. Only probable and proven invasive fungal diseases were included in these analyses. For consistency during the 20-year study period, allele-level typing for HLA-A, -B, and -DRB1 was performed to determine the degree of matching regardless of UCBT year.

Statistical Analysis

We categorized patients into 3 time periods based on year of UCBT (1995 to 2001, 2002 to 2007, 2008 to 2014). The probability of overall survival was estimated within these groups using the Kaplan-Meier method. We used chi-square or Fisher exact tests to evaluate for differences in patient and transplant characteristics across these time periods. We used a log-rank test to evaluate for a difference in overall survival by time period and a Gray's test to assess for a change in transplant-related mortality. Time at risk for analyses of overall survival was from the date of UCBT until death from any cause or censoring (eg, survival 2 years after UCBT). In analyses for which transplant-related mortality was the outcome of interest, patients with a malignant UCBT indication who died of primary disease were additionally censored.

We examined temporal trends in cause-specific mortality using Cochran-Armitage tests. We used multivariable Cox regression to identify demographic and UCBT clinical practices that were associated with all-cause mortality, transplant-related mortality, and death from invasive aspergillosis. In constructing these models we first evaluated for associations between the outcome and the following variables: age, sex, race, UCBT graft type (single versus double), UCBT indication (malignancy versus nonmalignancy), conditioning intensity (myeloablative versus reduced-intensity or nonmyeloablative), GVHD prophylaxis (regimen with corticosteroids versus regimen without corticosteroids), and antifungal prophylaxis regimen (amphotericin B lipid complex versus voriconazole).

We used multivariable Cox regression to evaluate demographic and donor selection factors that were associated with all-cause mortality. This analysis excluded transplants that included multiple UCB units or for which sex, race, or HLA data were missing from either the recipient or the donor. Final multivariable models included variables that were associated with the outcome in univariable analyses ($P < .20$). Using the time-dependent covariate approach we determined that the proportional odds assumption was violated for the models of all-cause and transplant-related mortality. To account for this we included time period and an interaction term between time period and days after UCBT in these models [11]. Analyses were performed using SAS software version 9.4 (SAS Institute, Cary, NC) and R version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria).

RESULTS
Patient Characteristics

During the 20-year study period 824 children (age <18 years) underwent their first UCBT. The most frequent malignant indications for UCBT were acute lymphoblastic leukemia (n = 182, 22%), acute myelogenous leukemia (n = 140, 17%), and myelodysplastic syndrome (n = 39, 5%). The most common nonmalignant indications were genetic or metabolic disorders (n = 245, 30%), nonmalignant hematologic disorders (n = 64, 8%), and immunodeficiencies (n = 93, 11%). Table 1 presents characteristics of the study population. We observed no significant differences in age, sex, or race by time period. In contrast, UCBT graft type ($P < .0001$), UCBT indication ($P < .0001$), conditioning intensity ($P < .0001$), GVHD prophylaxis regimen ($P < .0001$), and antifungal prophylaxis regimen ($P < .0001$) differed by time period. The proportion of children undergoing UCBT for malignancies declined during the study period. In the most recent time period (2008 to 2014) the number of patients receiving reduced-intensity conditioning regimens rose substantially.

Patient Outcomes

Three hundred sixty deaths (44%) occurred among the study population during the 2 years after UCBT. Overall survival after UCBT improved during the study period ($P = .0002$; Figure 1A). Two-year all-cause mortality was 48%, 39%, and 30% in 1995 to 2001, 2002 to 2007, and 2008 to 2014, respectively. Two-year transplant-related mortality was 41%, 30%, and 26% in 1995 to 2001, 2002 to 2007, and 2008 to 2014, respectively ($P = .001$; Figure 1B). Mortality from infection without GVHD ($P = .02$) and VOD ($P = .01$) declined during the study period (Table 2). Comparing 2008 to 2014 with 1995 to 2001, more than half (59%) of the reduced mortality of UCBT recipients was attributable to a reduction in infectious mortality. Graft failure contributed to 31 deaths (9%), and 43 children (5%) received a second UCBT because of graft failure.

In multivariable analyses race and UCBT indication were associated with 2-year all-cause mortality (Table 3). The hazard of death was higher for children of black race (hazard ratio [HR], 1.61; 95% confidence interval [CI], 1.20 to 2.16) and other racial minority groups (HR, 1.80; 95% CI, 1.35 to 2.40) than for white race. Black children tended to have a higher risk of death for which GVHD (18% versus 11%; $P = .06$) or graft failure (9% versus

Table 1
Characteristics of the Study Population

	Time Period						P
	1995-2001 (n = 298)		2002-2007 (n = 323)		2008-2014 (n = 203)		
	n	%	n	%	n	%	
Age							.29
<1 yr	47	16	43	13	29	14	
1-4 yr	100	34	138	43	72	35	
5-11 yr	97	33	98	30	71	35	
≥12 yr	54	18	44	14	31	15	
Sex							.48
Female	121	41	116	36	79	39	
Male	177	59	207	64	124	61	
Race							.13
White	219	73	230	71	134	66	
Black	44	15	51	16	29	14	
Other*	35	12	42	13	40	20	
UCBT graft type							<.0001
Single	289	100	324	97	156	77	
Double	0	0	9	3	47	23	
UCBT indication†							<.0001
Genetic or inherited metabolic disorders	50	17	117	36	78	39	
Immunodeficiency	35	12	28	9	30	15	
Malignancy	187	63	158	49	76	38	
Nonmalignant hematologic disorder	26	9	20	6	18	9	
Conditioning intensity‡							<.0001
Myeloablative	293	99	311	96	173	85	
Reduced-intensity	0	0	5	2	30	15	
Nonmyeloablative	3	1	7	2	0	0	
GVHD prophylaxis regimen§							<.0001
Cyclosporine and mycophenolate	0	0	113	35	137	67	
Cyclosporine and corticosteroids	283	96	198	61	36	18	
Other	12	4	12	4	30	15	
Antifungal prophylaxis regimen‖							<.0001
Amphotericin B lipid complex	275	98	117	37	0	0	
Voriconazole	4	1	190	60	196	97	
Other	3	1	11	3	6	3	

* Subjects of other racial minorities were Hispanic (n = 54), Asian (n = 37), Middle Eastern (n = 25), and Native American (n = 1).

† One subject underwent UCBT for an autoimmune disorder and was excluded from these analyses.

‡ Conditioning intensity was missing for 2 subjects.

§ GVHD prophylaxis regimen was missing for 3 subjects.

‖ Nineteen subjects had a preceding fungal infection and were excluded; 3 subjects were missing data

3%; P = .01) were contributory compared with white children. Children from other racial minority groups were more likely to die of organ failure (9% versus 2%; P = .001) and VOD (6% versus 1%; P = .01) than white children. With regard to UCBT indication the hazard of death was lower for nonmalignant conditions (HR, .74; 95% CI, .57 to .97) than for malignancies. Supplemental Table 1 presents predictors of transplant-related mortality in the study population. UCBT indication was not associated with transplant-related mortality.

White children were more likely to have a 5/6 or 6/6-matched donor than black children (56% versus 27%; P < .0001) or children from other racial minority groups (56% versus 42%; P = .01). White children were also more likely to receive a race-matched cord blood unit than black children (85% versus 56%; P < .0001) or children from other racial minorities (85% versus 32%; P < .0001). In univariable analyses 3/6 and 4/6 HLA matching (HR, 1.47; 95% CI, 1.17 to 1.86) and race mismatching (HR, 1.41; 95% CI, 1.11 to 1.81) were associated with higher 2-year all-cause mortality, whereas a cryopreserved total nucleated cell dose of ≥10.0 × 10⁷/kg was associated with lower mortality than a total nucleated cell dose of <5.0 × 10⁷/kg (HR, .69; 95% CI, .52 to .92). However, in multivariable analyses we did not observe any associations between these donor selection factors and 2-year all-cause mortality (Table 4).

Infectious Causes of Death

Table 5 shows infectious causes of death in the 2 years after UCBT. Fungi and viruses were the most frequent causes of infectious mortality. Most deaths from viral infections were from adenovirus (n = 50), cytomegalovirus (CMV; n = 27), and parainfluenza viruses (n = 14). Mortality from viral infections did not change during the study period (P = .70). In contrast, fungal mortality declined during the study period (P = .0001). Figure 2 shows mortality from invasive fungal infections by year of UCBT. Two-year mortality from invasive aspergillosis declined from 8% in 1995 to 2001 to <1% in 2002 to 2007 and 2008 to 2014 (P < .0001). Reduced mortality from invasive aspergillosis accounted for 45% of the reduction in mortality of children after UCBT between 1995 to 2001 and 2008 to 2014. In contrast, the 2-year mortality from *Candida* spp. and non-*Aspergillus* molds did not change over time (P = .86 and P = .56, respectively). In multivariable analyses (Table 6) antifungal prophylaxis with voriconazole was associated with lower mortality from invasive aspergillosis than prophylaxis with low-dose amphotericin B lipid complex (HR, .09; 95% CI, .01 to .76). This association between antifungal prophylaxis and death from invasive aspergillosis was independent of UCBT indication and GVHD prophylaxis regimen.

Figure 1. Probability of (A) overall survival and (B) transplant-related mortality after UCBT by year of transplantation. The *shaded areas* correspond to 95% CIs for the overall survival and transplant-related mortality curves for a given time period. Overall survival (log-rank test; $P = .0002$) and transplant-related mortality (Gray's test; $P = .001$) differed by time period. Specifically, overall survival was lower in 1995 to 2001 than in either 2002 to 2007 ($P = .01$) or 2008 to 2014 ($P = .0001$). Similarly, transplant-related mortality was higher in 1995 to 2001 compared with 2002 to 2007 ($P = .01$) and 2008 to 2014 ($P = .002$). Comparing 2002 to 2007 and 2008 to 2014, there were no significant differences in overall survival ($P = .06$) and transplant-related mortality ($P = .36$).

DISCUSSION

In this retrospective review of 824 children who underwent UCBT at a single center, overall survival improved substantially over the past 20 years. More than half of the improved survival was related to reduced mortality from infections, particularly invasive aspergillosis. Race was associated with lower mortality, even after accounting for donor selection characteristics.

Several prior studies demonstrated improved survival over time after allogeneic HSCT. Gooley et al. [12] reported that mortality among children and adults after allogeneic stem cell transplantation at the Fred Hutchinson Cancer Research Center fell 52% from 1993 to 1997 to 2003 to 2007. Similarly, 5-year overall survival among children who underwent allogeneic HSCT at a single institution improved from 52% to 64% between 1983 to 1999 and 2000 to 2010 [13]. Finally, using data reported to the Center for International Blood and Marrow Transplant Research, Horan et al. [14] found that the 2-year overall survival of children after unrelated donor bone marrow transplantation improved from 35% in 1987 to 1995 to 58% in 2003 to 2006. These studies consisted mostly of adults, were limited to patients with hematologic malignancies, included

Table 2
Causes of Death among the Study Population

	Time Period						
	1995-2001 (n = 298)		2002-2007 (n = 323)		2008-2014 (n = 203)		P
	n	%	n	%	n	%	
GVHD	3	1	2	1	3	1	.67
Hemorrhage	10	3	8	2	4	2	.33
Infection with GVHD	27	9	28	9	16	8	.65
Infection without GVHD	55	18	45	14	22	11	.02
Organ failure	9	3	12	4	5	2	.80
Primary disease	26	8	33	10	15	7	.70
VOD	12	4	5	2	1	<1	.01
Other	8	3	5	2	6	3	.95

Table 3
Multivariable Analyses Evaluating Associations Between Demographic and UCBT Practices and 2-Year All-Cause Mortality

	HR	(95% CI)	P
Time Period			
1995-2001	1.00	Ref	—
2002-2007	.46	(.30-.70)	.0004
2008-2014	.27	(.15-.49)	<.0001
Age			
<1 yr	1.00	Ref	—
1-4 yr	.84	(.60-1.19)	.32
5-11 yr	.72	(.49-1.06)	.09
≥12 yr	1.11	(.72-1.71)	.63
Race			
White	1.00	Ref	—
Black	1.61	(1.20-2.16)	.002
Other	1.80	(1.35-2.40)	<.0001
UCBT indication			
Malignancy	1.00	Ref	—
Nonmalignancy	.74	(.57-.97)	.03
Conditioning intensity			
Myeloablative	1.00	Ref	—
Reduced-intensity or nonmyeloablative	.80	(.45-1.43)	.43
GVHD prophylaxis			
Regimen with corticosteroids	1.00	Ref	—
Regimen without corticosteroids	.83	(.59-1.17)	.29
Antifungal prophylaxis			
Amphotericin B lipid complex	1.00	Ref	—
Voriconazole	1.24	(.84-1.85)	.28

Sex and UCBT graft type were not associated with all-cause mortality in univariable analyses. This multivariable model also adjusted for an interaction term between time period and days after UCBT.

relatively few UCBT recipients, or did not include data from the past 10 years [12-16]. In this study we present detailed data on causes of death in the largest single-center cohort of pediatric UCBT recipients reported to date. Although broadly consistent

Table 4
Multivariable Analyses of Factors for Demographic and Donor Selection Characteristics and 2-Year All-Cause Mortality in 667 Children Who Underwent Single UCBT

	HR	(95% CI)	P
Time Period			
1995-2001	1.00	Ref	—
2002-2007	.51	(.35-.74)	.0003
2008-2014	.38	(.21-.69)	.001
Age			
<1 yr	1.00	Ref	—
1-4 yr	.90	(.61-1.31)	.57
5-11 yr	.72	(.45-1.18)	.19
≥12 yr	.99	(.56-1.74)	.97
Race			
White	1.00	Ref	—
Black	1.49	(1.08-2.07)	.02
Other	1.74	(1.23-2.45)	.002
UCBT indication			
Malignancy	1.00	Ref	—
Nonmalignancy	.70	(.52-.92)	.01
Cryopreserved TNC			
<5.0 × 10^7 TNC/kg	1.00	Ref	—
5.0-9.9 × 10^7 TNC/kg	1.03	(.74-1.42)	.88
≥10.0 × 10^7 TNC/kg	.89	(.59-1.36)	.59
HLA matching			
5/6 or 6/6	1.00	Ref	—
3/6 or 4/6	1.21	(.95-1.56)	.13
Race matching*			
Matched	1.00	Ref	—
Mismatched	1.14	(.87-1.49)	.35

Sex and sex matching were not associated with all-cause mortality in univariable analyses. This multivariable model also adjusted for an interaction term between time period and days after UCBT. TNC indicates total nucleated cells.
* Racial categories considered for these analyses were white, black, Hispanic, Asian, Middle Eastern, and Native American.

Table 5
Infectious Causes of Death after UCBT by Time Period

	Time Period						
	1995-2001		2002-2007		2008-2014		P
	n	%	n	%	n	%	
Bacteria	18	6	15	5	9	4	.39
Gram-negative	9	3	10	3	3	1	
Gram-positive	8	3	3	1	6	3	
Polymicrobial	1	<1	2	1	0	0	
Fungi	32	11	11	3	6	3	.0001
Aspergillus spp.	23	8	3	1	2	1	
Candida spp.	4	1	7	2	2	1	
Non-Aspergillus molds	4	1	1	<1	2	1	
Parasites	3	1	1	<1	1	<1	.41
Viruses*	29	10	43	13	21	10	.70
Adenovirus	12	4	27	8	11	5	
CMV	7	2	12	4	8	4	
Herpes simplex	2	1	4	1	0	0	
Parainfluenza	5	2	6	2	3	1	
Other	4	1	0	0	5	2	
Suspected infection, no organism identified	10	3	7	2	7	3	.95
Pneumonia	5	2	5	2	3	1	
Sepsis	5	2	2	1	4	2	

Number of deaths may not sum to the deaths from infection in Table 2 because multiple infections were identified for some subjects.
* Deaths from specific viruses may not sum to category heading because some children had more than 1 virus identified as a primary cause of death.

with the findings from these other studies, our results indicate that overall survival among children after UCBT improved substantially at our institution over the past 2 decades.

Mortality from invasive aspergillosis among children receiving UCBT fell markedly during the 20-year study period. Between 1995 to 2001 and 2008 to 2014, 2-year mortality from aspergillosis declined from 8% to <1%. This reduction in mortality was strongly associated with use of voriconazole for antifungal prophylaxis in the study population. Importantly, we found that this effect of voriconazole prophylaxis on mortality from invasive aspergillosis was independent of UCBT indication and other major changes in clinical practice, including a shift away from use of steroids for GVHD prophylaxis. The efficacy of voriconazole for antifungal prophylaxis was previously reported in observational studies [17,18]. However, voriconazole did not lower the incidence of invasive fungal infection during the first 180 days after allogeneic stem cell transplantation compared with fluconazole in a randomized controlled trial, which could be related to subtherapeutic voriconazole dosing or an insufficient duration of follow-up in this trial [19]. Our results suggest that voriconazole effectively prevents invasive aspergillosis mortality among children after UCBT.

With the decline in mortality from invasive aspergillosis, adenovirus and CMV have become the dominant infectious causes of death in children after UCBT. These 2 viruses accounted for 19 of 72 deaths (26%) occurring in the most recent time period (2008 to 2014). There has been little progress in the prevention and treatment of these viral infections over the past several decades. There is no US Food and Drug Administration−approved therapy for adenovirus infection. Cidofovir has been available for off-label use since 1996; however, adenovirus-related mortality remains high in allogeneic stem cell transplant recipients despite cidofovir, and this antiviral medication is associated with severe renal toxicity [20,21]. The standard medications for the prevention and treatment of CMV disease in allogeneic stem cell transplant

Figure 2. Two-year mortality from invasive fungal infections among children undergoing UCBT by year of transplantation. Mortality from invasive aspergillosis declined during the study period (*P* < .0001), whereas the mortalities from *Candida* species and non-*Aspergillus* molds did not differ by year of transplantation

recipients are ganciclovir and foscarnet, antiviral medications that were available throughout the study period. However, neither of these medications have proved effective for CMV prevention after stem cell transplantation, and both are associated with substantial toxicity. Several novel therapeutics have the potential to lower mortality from adenovirus and CMV infections. Brincidofovir, a derivative of cidofovir without the associated renal toxicity, has potent activity against adenovirus, although further study is needed before it can be recommended routinely for these infections [22]. Letermovir, a novel anti-CMV agent, was approved by the US Food and Drug Administration for prevention of CMV infection and disease in adult HSCT patients, but data on dosing and efficacy are not yet available for children [23]. Finally, virus-specific T lymphocytes have been used for the prevention and treatment of adenovirus and CMV infections in allogeneic stem cell transplant recipients, and evaluation of these products is ongoing [24].

A key finding in this study is that black children and children from other racial minority groups had higher all-cause mortality than white children. Numerous prior studies described racial disparities in allogeneic HSCT [25−28]. Multiple contributing

factors have been proposed including a lower likelihood of finding an unrelated HLA-matched donor, lower socioeconomic status, provider bias, and structural factors within the healthcare system [29]. We found that black children and children from other racial minorities were more likely to receive 3/6 or 4/6 HLA-matched and race-mismatched cord blood units than white children and that receipt of these units was associated with higher mortality in univariable analyses. However, these associations did not persist in multivariable analyses adjusting for race and other patient characteristics. Two prior studies also did not find an association between donor race matching and mortality after HSCT [30,31]. However, in these studies race matching data were missing for a large portion (about 30%) of the analytic sample [30] or only racial minorities comprised of a small part of the analytic cohort (13%) [31]. Similarly, less than 30% of our sample included nonwhite children. To allow to a more detailed examination of the effect of race mismatching on mortality, future research should include a greater representation of racial minorities. These findings lend further support to ongoing initiatives to improve the representation of racial minority groups in UCB registries [32].

Our study has several limitations. First, it was conducted at a single academic hospital, the transplant practices of which may not be reflective of those at other transplant centers. Furthermore, the indications for UCBT changed over time at our center, with a declining proportion of transplants performed for malignancy. This trend could have contributed to the improved survival of patients over time and could reflect both the increasing use of UCBT for nonmalignant conditions and the growing number of centers performing UCBT [33]. Moreover, although we reviewed autopsy reports, provider notes, and the results of microbiologic testing for all deceased subjects, misclassification of the cause of death remains possible. In addition, analyses of the infectious causes of death did not account for changes in the diagnostic testing available for specific infections, particularly invasive fungal and viral infections. The availability of these assays in the later years of this study could have led to the improved diagnosis of fatal invasive fungal or viral infections or, alternatively, earlier diagnosis and

Table 6
Multivariable Analyses Evaluating Associations Between Demographic and UCBT Characteristics and 2-Year Mortality from Invasive Aspergillosis

	HR	(95% CI)	*P*
Age			
<12 yr	1.00	Ref	—
≥12 yr	4.88	(2.09-11.39)	.0003
UCBT indication			
Malignancy	1.00	Ref	—
Nonmalignancy	.52	(.18-1.49)	.22
GVHD prophylaxis			
Regimen with corticosteroids	1.00	Ref	—
Regimen without corticosteroids	1.00	(.11-9.46)	.99
Antifungal prophylaxis			
Amphotericin B lipid complex	1.00	Ref	—
Voriconazole	.08	(.01-.76)	.03

Sex, race, UCBT graft type, and conditioning intensity were not associated with mortality from invasive aspergillosis in univariable analyses.

improved survival from these infections [34−37]. We did not have data on the incidence of invasive aspergillosis in this population and are thus unable to determine the extent to which the decline in mortality is attributable to prevention of *Aspergillus* infections rather than improved treatment outcomes. Although the dose of voriconazole used for antifungal prophylaxis was standardized, plasma trough voriconazole levels were not routinely followed. Given the substantial intraindividual variability in voriconazole metabolism, we are unable to more precisely determine associations between voriconazole exposures and invasive aspergillosis [38]. Moreover, because the overwhelming majority of children in this cohort received amphotericin B lipid complex or voriconazole for antifungal prophylaxis, we are unable to compare the effectiveness of these medications with other antifungal agents. Finally, for consistency across the 20-year study period, we determined degree of HLA matching based only on allele-level typing of HLA-A, -B, and -DRB1. Typing of HLA-C and -DQB1 is currently performed at our center and many other institutions, and it is unclear if the lack of association between HLA matching and mortality after UCBT would persist after accounting for matching at these additional HLA loci.

Clinical advances over the past 20 years have substantially improved survival of children after UCBT, further supporting its use as a stem cell source for children who do not have a matched sibling or unrelated donor. Routine use of voriconazole prophylaxis was associated with a dramatic reduction in mortality from invasive aspergillosis. However, there is still an urgent need for improved strategies for the prevention and treatment of adenovirus, CMV, and GVHD. Future research should focus on whether the development of new commercial molecular assays for adenovirus and CMV has led to improved survival in this high-risk patient population.

SUPPLEMENTARY DATA

Supplementary data related to this article can be found online at doi:10.1016/j.bbmt.2018.11.018.

REFERENCES

1. D'Souza A, Fretham C. Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR summary slides; 2017. Available at: http://www.cibmtr.org. Accessed June 24, 2018.
2. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. *Blood*. 2013;122:491–498.
3. Gluckman E, Rocha V, Boyer-Chammard A, et al. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. Outcome of cord-blood transplantation from related and unrelated donors. *N Engl J Med*. 1997;337:373–381.
4. Rocha V, Cornish J, Sievers EL, et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. *Blood*. 2001;97:2962–2971.
5. Hwang WY, Samuel M, Tan D, Koh LP, Lim W, Linn YC. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. *Biol Blood Marrow Transplant*. 2007;13:444–453.
6. Ruggeri A, Eapen M, Scaravadou A, et al. Eurocord Registry; Center for International Blood and Marrow Transplant Research; New York Blood Center. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. *Biol Blood Marrow Transplant*. 2011;17:1375–1382.
7. Gluckman E, Rocha V, Ionescu I, et al. Eurocord-Netcord and EBMT. Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival. *Biol Blood Marrow Transplant*. 2007;13:1073–1082.
8. Richardson PG, Soiffer RJ, Antin JH, et al. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. *Biol Blood Marrow Transplant*. 2010;16:1005–1017.
9. Horvath MM, Winfield S, Evans S, Slopek S, Shang H, Ferranti J. The DEDUCE Guided Query tool: providing simplified access to clinical data for research and quality improvement. *J Biomed Inform*. 2011;44:266–276.
10. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group. *Clin Infect Dis*. 2008;46:1813–1821.
11. Bradburn M, Clark T, Love S, Altman D. Survival analysis part III: multivariate data analysis—choosing a model and assessing its adequacy and fit. *Br J Cancer*. 2003;89:605.
12. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. *N Engl J Med*. 2010;363:2091–2101.
13. Brissot E, Rialland F, Cahu X, et al. Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution. *Bone Marrow Transplant*. 2016;51:267–272.
14. Horan JT, Logan BR, Agovi-Johnson M-A, et al. Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? *J Clin Oncol*. 2011;29:805–813.
15. Hahn T, McCarthy Jr TL, Hassebroek A, et al. Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. *J Clin Oncol*. 2013;31:2437–2449.
16. MacMillan ML, Davies SM, Nelson GO, et al. Twenty years of unrelated donor bone marrow transplantation for pediatric acute leukemia facilitated by the National Marrow Donor Program. *Biol Blood Marrow Transplant*. 2008;14(9 Suppl):16–22.
17. Siwek GT, Pfaller MA, Polgreen PM, et al. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis. *Diagn Microbiol Infect Dis*. 2006;55:209–212.
18. Martin T, Sharma M, Damon L, et al. Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation. *Transpl Infect Dis*. 2010;12:45–50.
19. Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. *Blood*. 2010;116:5111–5118.
20. Symeonidis N, Jakubowski A, Pierre-Louis S, et al. Invasive adenoviral infections in T-cell-depleted allogeneic hematopoietic stem cell transplantation: high mortality in the era of cidofovir. *Transpl Infect Dis*. 2007;9:108–113.
21. Ljungman P, Ribaud P, Eyrich M, et al. Cidofovir for adenovirus infections after allogeneic hematopoietic stem cell transplantation: a survey by the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. *Bone Marrow Transplant*. 2003;31:481–486.
22. Grimley MS, Chemaly RF, Englund JA, et al. Brincidofovir for asymptomatic adenovirus viremia in pediatric and adult allogeneic hematopoietic cell transplant recipients: a randomized placebo-controlled phase II trial. *Biol Blood Marrow Transplant*. 2017;23:512–521.
23. Chemaly RF, Ullmann AJ, Stoelben S, et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. *N Engl J Med*. 2014;370:1781–1789.
24. Leen AM, Bollard CM, Mendizabal AM, et al. Multicenter study of banked third party virus-specific T-cells to treat severe viral infections after hematopoietic stem cell transplantation. *Blood*. 2013;121:5113–5123.

25. Ballen KK, Klein JP, Pedersen TL, et al. ethnicity /ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes. *Biol Blood Marrow Transplant*. 2012;18:903–912.
26. Barker JN, Byam CE, Kernan NA, et al. Availability of cord blood extends allogeneic hematopoietic stem cell transplant access to racial and ethnic minorities. *Biol Blood Marrow Transplant*. 2010;16:1541–1548.
27. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the US registry. *N Engl J Med*. 2014;371: 339–348.
28. Ballen KK, Klein JP, Pedersen TL, et al. ethnicity /ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes. *Biol Blood Marrow Transplant*. 2012;18:903–912.
29. Majhail N, Nayyar S, Santibanez MB, Murphy E, Denzen E. Racial disparities in hematopoietic cell transplantation in the United States. *Bone Marrow Transplant*. 2012;47:1385–1390.
30. Ballen KK, Klein JP, Pedersen TL, et al. ethnicity /ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes. *Biol Blood Marrow Transplant*. 2012;18:903–912.
31. Ustun C, Bachanova V, Shanley R, et al. Importance of donor ethnicity/race matching in unrelated adult and cord blood allogeneic hematopoietic cell transplant. *Leuk Lymph*. 2014;55:358–364.
32. National Marrow Donor Program. Donor registry data. Available at: https://bloodcell.transplant.hrsa.gov/research/registry_donor_data/index. html. Accessed August 22, 2017.
33. D'Souza A, Lee S, Zhu X, Pasquini M. Current use and trends in hematopoietic cell transplantation in the United States. *Biol Blood Marrow Transplant*. 2017;23:1417–1421.
34. Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after heamopoietic stem cell transplantation in the era of preemptive therapy: a retrospective cohort study. *Lancet Haematol*. 2016;3: e119–e127.
35. Jha AK, Bansal D, Chakrabarti A, Shivaprakash M, Trehan A, Marwaha RK. Serum galactomannan assay for the diagnosis of invasive aspergillosis in children with haematological malignancies. *Mycoses*. 2013;56:442–448.
36. Feghoul L, Chevret S, Cuinet A, et al. Adenovirus infection and disease in paediatric haematopoietic stem cell transplant patients: clues for antiviral pre-emptive treatment. *Clin Microbiol Infect*. 2015;21:701–709.
37. Guitard J, Tabone M-D, Senghor Y, et al. Detection of β-D-glucan for the diagnosis of invasive fungal infection in children with hematological malignancy. *J Infect*. 2016;73:607–615.
38. Gautier-Veyret, Fonrose X, Tonini J, et al. Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels. *Antimicrob Agents Chemother*. 2015;59:2305–2314.